Clinical trials: Mutation
Pancreatic Ductal Adenocarcinoma
DC Vaccine in Pancreatic Cancer
This research study is designed to evaluate the effects of a dendritic cell (kind of white blood cell) vaccine for pancreatic cancer.
- Trial name
- NCT03592888
- Testing
- mDC3/8-KRAS Vaccine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Pennsylvania
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Bladder Cancer, Melanoma
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
The purpose of this study is to investigate the characteristics of tumors in patients treated with nivolumab and to identify features that help to predict a good or bad response to this drug.
- Trial name
- NCT02553642
- Testing
- Nivolumab, Nivolumab plus Ipilimumab
- Where
- 5 sites in United States
- Volunteers
- 81 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant Astrocytoma
RATIONALE: IL-4(38-37)-PE38KDEL immunotoxin may locate tumor cells and kill them without harming normal cells. This may be an effective treatment for recurrent malignant astrocytoma.
- Trial name
- NCT00003842
- Testing
- interleukin-4 PE38KDEL cytotoxin, isolated perfusion, surgical procedure
- Where
- 10 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barrett Cancer Center
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
The clinical trial is a phase 1, single-arm trial that will evaluate the safety of the investigational treatment on metastatic pancreatic cancer and metastatic breast cancer.
- Conditions
- Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation, Pancreatic Acinar Cell Carcinoma
- Trial name
- SHARON (NCT04150042)
- Testing
- Melphalan, BCNU, Vitamin B12B
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- General Oncology, Inc.
Parkinson Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease
The main goal of this clinical trial is to learn about the safety and tolerability of GT-02287. The questions it aims to answer are: What medical problems do participants have when taking GT-02287? How is GT-02287 absorbed…
- Trial name
- NCT06732180
- Testing
- GT-02287
- Where
- 7 sites in Australia
- Volunteers
- 20 people
- Sponsor
- Gain Therapeutics, Inc.
Colo-rectal Cancer, Polygenic Risk Score
Development of Polygenic Risk Scores in Colon Cancer Patients Through the Study of Ancestry and Diversity in Genetic Maps of the Brazilian Population - ORIGEM Project
Development of a polygenic risk score based on somatic and germline genetic information from patients with colorectal cancer
- Conditions
- Colo-rectal Cancer, Polygenic Risk Score, Somatic Mutation, Hereditary Cancer
- Trial name
- ORIGEM (NCT06917794)
- Where
- 9 sites in Brazil
- Volunteers
- 500 people
- Sponsor
- D'Or Institute for Research and Education
Endometrial Cancer Recurrent
Crizotinib in c-MET Mutation Metastatic/Recurrent/Persistent Endometrial Cancer
The majority of endometrial cancer patients with disease spread beyond the uterus will progress within 1 year. Platinum-based chemotherapy was used as the first-line treatment in metastatic or advanced endometrial cancer.
- Trial name
- NCT04030429
- Testing
- Crizotinib 250 MG
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Cheng-Kung University Hospital
Triple-Negative Breast Cancer, Squamous Cell Lung Cancer
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
Open-label, multicentre phase Ib/IIa study of AZD2014 administered with selumetinib. There are two parts to this study: a dose-escalation part in treatment-refractory advanced solid tumours and a subsequent separate expansion…
- Conditions
- Triple-Negative Breast Cancer, Squamous Cell Lung Cancer, Non-squamous Cell Lung Cancer With KRAS Mutations, Non-squamous Cell Lung Cancer With Wild-type KRAS
- Trial name
- TORCMEK (NCT02583542)
- Testing
- AZD2014, AZD6244
- Where
- 4 sites in United Kingdom
- Volunteers
- 118 people
- Sponsor
- Queen Mary University of London
Non-small Cell Lung Cancer (NSCLC)
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung…
- Trial name
- NCT06305754
- Testing
- Sacituzumab tirumotecan, Pemetrexed, Carboplatin
- Where
- 156 sites in United States, Argentina and 17 more
- Volunteers
- 550 people
- Sponsor
- Merck Sharp & Dohme LLC
Cystic Fibrosis
Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study. The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive…
- Trial name
- ROSCO-CF (NCT02649751)
- Testing
- Roscovitine
- Where
- 11 sites in France
- Volunteers
- 49 people
- Sponsor
- University Hospital, Brest
Advanced Solid Tumors, Breast Cancer
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
This is a Phase 1, open-label study to evaluate the safety and tolerability of ATV-1601 administered orally in adults with AKT1 E17K-mutant, advanced solid tumors and also in HR+/HER2- advanced and metastatic breast cancer, with…
- Conditions
- Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
- Trial name
- NCT07038369
- Testing
- ATV-1601, ATV-1601 + Fulvestrant
- Where
- 8 sites in United States, France and 2 more
- Volunteers
- 134 people
- Sponsor
- Atavistik Bio, Inc
Metastatic Melanoma, Melanoma
Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib
The purpose of this study is to see if the combination of Vemurafenib with Decitabine plus Cobimetinib improves the low therapy response rate in subjects with malignant melanoma.
- Conditions
- Metastatic Melanoma, Melanoma, BRAF-mutated Metastatic Melanoma, V600EBRAF-mutated Metastatic Melanoma
- Trial name
- ML28604 (NCT01876641)
- Testing
- Vemurafenib + Cobimetinib, Decitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mohammed M Milhem
Solid Tumor, Breast Tumor
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
- Conditions
- Solid Tumor, Breast Tumor, Colon Tumor, Malignant, Lung Tumor
- Trial name
- PAVO (NCT05169437)
- Testing
- Niraparib
- Where
- 80 sites in United States
- Volunteers
- 22 people
- Sponsor
- Tempus AI
Lung Non-Squamous Non-Small Cell Carcinoma
Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer
This phase II trial tests how well zipalertinib with carboplatin and pemetrexed works in treating stage II-IIIB non small cell lung cancer. that can be removed by surgery (resectable).
- Trial name
- NCT07229339
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Breast Cancer, Invasive Breast Cancer
Olaparib In Metastatic Breast Cancer
This research study is for patients with metastatic breast cancer. Metastatic means that the cancer has spread beyond the breast.
- Conditions
- Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2)
- Trial name
- NCT03344965
- Testing
- Olaparib
- Where
- 20 sites in United States
- Volunteers
- 114 people
- Sponsor
- Beth Israel Deaconess Medical Center
Azoospermia, Nonobstructive, Cryptozoospermia
Maternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men
Idiopathic non-obstructive azoospermia and cryptozoospermia are severe forms of male infertility in which sperm production is absent or extremely low and the cause is often unknown.
- Trial name
- MTND1-INA/C (NCT07691827)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Non-small Cell Lung Cancer
A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)
The goal of this clinical trial is to test if PLB1001 works well and safely in Non-small cell lung cancer patients with MET exon 14 mutation.
- Trial name
- KUNPENG-2 (NCT05989542)
- Testing
- PLB1001
- Where
- China
- Volunteers
- 136 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Metastatic HPV-16 Positive Squamous Cell Anal Cancer
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
Background: A cancer treatment has been developed called "gene transfer" or "gene therapy." It involves taking white blood cells from a person (called apheresis), genetically modifying the cells in a lab to recognize cancer, and…
- Trial name
- NCT04536922
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
The primary objective of this study is to evaluate the safety of lanraplenib (LANRA) in combination with the FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib, in participants with relapsed or refractory (R/R) FLT3-mutated…
- Conditions
- Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Trial name
- NCT05028751
- Testing
- Lanraplenib, Gilteritinib
- Where
- 17 sites in United States, Spain
- Volunteers
- 24 people
- Sponsor
- Kronos Bio